Eur Rev Med Pharmacol Sci 2020; 24 (15): 7923-7924
DOI: 10.26355/eurrev_202008_22473

Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA)

S.A. Dar, M. Wahid, S. Haque, S.S. Almalki, N. Akhter

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia. naseem.du@gmail.com

Free PDF Download

To cite this article

S.A. Dar, M. Wahid, S. Haque, S.S. Almalki, N. Akhter
Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA)

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 15
Pages: 7923-7924
DOI: 10.26355/eurrev_202008_22473

Keywords Related articles:

  1. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
  2. Diospyros lotus L. fruit extract protects G6PD-deficient erythrocytes from hemolytic injury in vitro and in vivo: prevention of favism disorder
  3. No infectious risk of COVID-19 patients with long-term fecal 2019-nCoV nucleic acid positive
  4. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections
  5. Defining the burden of olfactory dysfunction in COVID-19 patients